China's Sinovac enters supply deal with Indonesia for COVID-19 vaccine doses
Aug 25 (Reuters) - Sinovac Biotech Ltd SVA.O said on Tuesday it would help Indonesia's state-owned drugmaker Bio Farma produce in the country at least 40 million doses of its potential coronavirus vaccine before March 2021.
The U.S.-listed Chinese drugmaker has signed two agreements with Bio Farma for supply, local production and technology licensing of its vaccine candidate CoronaVac and the Indonesian company is conducting the late-stage study of the candidate.
Sinovac will continue to supply the bulk vaccine until the end of 2021 after March, it said in a statement.
There are no approved vaccine for COVID-19, with drugmakers and research organizations racing to develop a safe and effective vaccine that is seen as crucial to combat the pandemic.
CORRECTED-UPDATE 1-Indonesia books 50 mln coronavirus vaccine doses from Sinovac
FACTBOX- The race for a coronavirus vaccine
FACTBOX-U.S., UK spend billions to take lead in securing coronavirus vaccines
(Reporting by Ankur Banerjee in Bengaluru; Editing by Arun Koyyur)
((ankur.banerjee@thomsonreuters.com;; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132; Twitter: @AnkurBanerjee17;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In This Story
SVALatest Markets Videos
Explore US Markets
ExploreMost Popular
- Tesla removed from S&P 500 ESG index on autopilot, discrimination concerns
- US STOCKS-Wall Street ends sharply lower as Target and growth stocks sink
- Powell says Fed to 'keep pushing' rates higher until clear inflation is falling
- Fed could cut rates in 2023, 2024 once inflation under control -Bullard